A Study to Investigate the Potential Pharmacokinetic Interactions Between

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the potential pharmacokinetic (what the body does to the drug) interactions between multiple doses of phenytoin 200 mg every 12 hours or carbamazepine 200 mg every 12 hours and telaprevir 750 mg every 8 hours at steady-state (constant concentration of medication in the blood) in healthy participants.

Clinical Trial Description

This is a Phase I, open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), 2-panel, sequential treatment study. In this study 24 healthy participants will be randomly assigned equally to 2 panels. In Panel 1 the participants will receive telaprevir in Part 1 (telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750 mg dose in the morning on Day 10) and phenytoin/telaprevir in Part 2 (phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750 mg dose in the morning on Day 17). In Panel 2 the participants will receive telaprevir (telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750 mg dose in the morning on Day 10) and carbamazepine/ telaprevir (carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 200-mg dose in the morning on Day 17). In both panels, Part 1 and Part 2 are separated by a washout period of at least 2 weeks and maximum 4 weeks. Safety and tolerability will be assessed by evaluating adverse events, electrocardiogram, clinical laboratory examinations, vital signs and physical examination throughout the study period. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Healthy Participants

Clinical Trial Details

NCT number	NCT01635829
Study type	Interventional
Source	Janssen Infectious Diseases BVBA
Contact
Status	Completed
Phase	Phase 1
Start date	May 2012
Completion date	September 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05445440` - A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine	Phase 1
Completed	`NCT03712540` - An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants	Phase 1
Completed	`NCT03649165` - A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants	Phase 1
Completed	`NCT05956002` - A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants	Phase 1
Completed	`NCT05539976` - A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
Withdrawn	`NCT04558216` - Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants	Phase 1
Withdrawn	`NCT03007771` - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia	Phase 1
Completed	`NCT06097390` - A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III	Phase 1
Completed	`NCT05546151` - A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent	Phase 1
Completed	`NCT05056246` - Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants	Phase 1
Completed	`NCT04390776` - Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.	Phase 1
Completed	`NCT05074459` - A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines	Phase 1
Enrolling by invitation	`NCT06089109` - Creating VIP Corps to Reduce Maternal Deaths	N/A
Completed	`NCT05996250` - Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects	N/A
Completed	`NCT03278080` - Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1	N/A
Completed	`NCT05064800` - PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants	Phase 1
Completed	`NCT04471298` - A Study of Qishenyiqi Dripping Pills in Healthy Participants	Phase 1
Completed	`NCT04914936` - A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196	Phase 1
Completed	`NCT01681186` - A Study of LY2940680 in Healthy Participants	Phase 1
Completed	`NCT02563262` - Human Neutral Body Posture in Weightlessness	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms